On 22 July 2024, the European Commission (EC) announced that it will be imposing certain commitments on Vifor, a manufacturer of intravenous iron medicines. Vifor is a dominant player in this market and had spread misleading information about the safety of a competing drug, Monofer, to healthcare professionals. The EC had opened an investigation, suspecting a potential […]
We advised Haut.AI on data protection and contractual matters, as well as in negotiations with a global consumer goods company whose products are used by over 1 billion customers daily. AI-powered image analysis can revolutionize skincare commerce Estonian based Haut.AI provides a B2B SaaS product that automates the collection of high-quality skin data, conducts a […]
The discussion surrounding the lack of funding in Estonian healthcare and its deterioration is intensifying, with potential solutions being cautiously presented. We are partnering with AstraZeneca and the American Chamber of Commerce (AmCham) to find new, cross-sector solutions to Estonian healthcare funding challenges. Through our new healthcare platform, we are specifically looking for ideas that […]
We advised shareholders of Stebby on the sale of Stebby’s majority shareholding to French rewards and benefits leader Up Group. As part of the transaction, the previous majority owner of Stebby, Livonia Partners, has exited. The management team will continue to run the company together with the new partner, enabling it to expand its presence […]
This month’s Life Sciences & Healthcare newsletter bring you a short overview of how off-label use of medicinal products is regulated in the Baltics. This is especially interesting in the light of the recent judgement of the European Court of Justice on off-label use of medicinal products. Risk-benefit balance includes risks resulting from off-label use The […]
